stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) Current ratio
LivaNova PLC's current ratio at the end of the quarter to 30 September 2026 was 1.7×, up 0.4× from fiscal 2025 (1.4×). Over the past ten years it has ranged from 1.0× (fiscal 2021) to 7.7× (fiscal 2015); the current reading is higher than 33% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.4× | (52.57%) |
| FY2024 | 2.9× | (2.55%) |
| FY2023 | 2.9× | (1.00%) |
| FY2022 | 3.0× | 205.76% |
| FY2021 | 1.0× | (57.46%) |
| FY2020 | 2.3× | 113.71% |
| FY2019 | 1.1× | (0.15%) |
| FY2018 | 1.1× | (49.89%) |
| FY2017 | 2.1× | (7.76%) |
| FY2016 | 2.3× | 23.86% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.7× | 20.07% |
| Jun 2026 | 1.4× | 8.99% |
| Mar 2026 | 1.3× | (2.43%) |
| Dec 2025 | 1.4× | 2.84% |
| 44 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| AXGN AxoGen, Inc. compare | 12.0× |
| TXG 10x Genomics compare | 5.7× |
| ITGR Integer Holdings Corporation compare | 4.0× |
| NEOG Neogen Corporation compare | 3.9× |
| IRTC iRhythm Holdings, Inc. compare | 3.6× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.2× |
| HAE Haemonetics Corporation compare | 2.8× |
| BRKR Bruker Corporation compare | 1.8× |
| LIVN LivaNova PLC | 1.7× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement